The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Self-citationThe DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Role of poly(ADP-ribose) formation in DNA repair
Satoh, M. S., & Lindahl, T. (1992) · Nature · doi:10.1038/356356a0 · Cited by 1,174
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Helleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 856
Drugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
Self-citationNewlands, E. S., Stevens, M. F. G., Wedge, S. R., Wheelhouse, R. T., & Brock, C. (1997) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(97)90019-0 · Cited by 817
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow, J. H., & Pommier, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 756
Self-citationIncreased ratio of targeted to random integration after transfection of chicken B cell lines
Buerstedde, J.-M., & Takeda, S. (1991) · Cell · doi:10.1016/0092-8674(91)90581-i · Cited by 538
Self-citationTopoisomerase I poisoning results in PARP-mediated replication fork reversal
Ray Chaudhuri, A., Hashimoto, Y., Herrador, R., Neelsen, K. J., Fachinetti, D., Bermejo, R., Cocito, A., Costanzo, V., & Lopes, M. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2258 · Cited by 499
Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition
Berti, M., Ray Chaudhuri, A., Thangavel, S., Gomathinayagam, S., Kenig, S., Vujanovic, M., Odreman, F., Glatter, T., Graziano, S., Mendoza-Maldonado, R., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2501 · Cited by 452
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Curtin, N. J., & Szabo, C. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.006 · Cited by 369
PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
Brenner, J. C., Feng, F. Y., Han, S., Patel, S., Goyal, S. V., Bou-Maroun, L. M., Liu, M., Lonigro, R., Prensner, J. R., Tomlins, S. A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3648 · Cited by 290
Parp‐1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells
Hochegger, H., Dejsuphong, D., Fukushima, T., Morrison, C., Sonoda, E., Schreiber, V., Zhao, G. Y., Saberi, A., Masutani, M., Adachi, N., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601015 · Cited by 276
Self-citationOxidative DNA damage repair in mammalian cells: A new perspective
HAZRA, T., DAS, A., DAS, S., CHOUDHURY, S., KOW, Y., & ROY, R. (2007) · DNA Repair · doi:10.1016/j.dnarep.2006.10.011 · Cited by 264
PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage
Das, B. B., Huang, S.-Y. N., Murai, J., Rehman, I., Amé, J.-C., Sengupta, S., Das, S. K., Majumdar, P., Zhang, H., Biard, D., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku088 · Cited by 225
Self-citationPARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
Sugimura, K., Takebayashi, S.-I., Taguchi, H., Takeda, S., & Okumura, K. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200806068 · Cited by 211
Self-citationMurai, J., Huang, S.-Y. N., Das, B. B., Dexheimer, T. S., Takeda, S., & Pommier, Y. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.333963 · Cited by 181
Self-citationHastak, K., Alli, E., & Ford, J. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4521 · Cited by 176
Pettitt, S. J., Rehman, F. L., Bajrami, I., Brough, R., Wallberg, F., Kozarewa, I., Fenwick, K., Assiotis, I., Chen, L., Campbell, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061520 · Cited by 172
Zhang, Y.-W., Regairaz, M., Seiler, J. A., Agama, K. K., Doroshow, J. H., & Pommier, Y. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1304 · Cited by 164
Self-citationAdvances in using PARP inhibitors to treat cancer
Kummar, S., Chen, A. P., Parchment, R. E., Kinders, R. J., Ji, J., Tomaszewski, J. E., & Doroshow, J. H. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-25 · Cited by 151
Self-citationBowman, K. J., Newell, D. R., Calvert, H., & Curtin, N. J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1555 · Cited by 144
Maede, Y., Shimizu, H., Fukushima, T., Kogame, T., Nakamura, T., Miki, T., Takeda, S., Pommier, Y. G., & Murai, J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0551 · Cited by 142
Self-citationSmith, L. M., Willmore, E., Austin, C. A., & Curtin, N. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1224 · Cited by 139
Boulton, S. J., Pemberton, L., Porteous, J. K., Curtin, N. J., Griffin, R., Golding, B. T., & Durkacz, B. W. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.423 · Cited by 136
Poly(ADP-ribose) Reactivates Stalled DNA Topoisomerase I and Induces DNA Strand Break Resealing
Malanga, M., & Althaus, F. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300437200 · Cited by 135
Liu, X., Han, E. K.-H., Anderson, M. G., Shi, Y., Semizarov, D., Wang, G., McGonigal, T. P., Roberts, L., Lasko, L. M., Palma, J. P., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0299 · Cited by 102
Cistulli, C. A., Lavrik, O. I., Prasad, R., Hou, E. W., & Wilson, S. H. (2004) · DNA repair · doi:10.1016/j.dnarep.2003.09.012 · Cited by 94
Increased PARP-1 Association with DNA in Alkylation Damaged, PARP-Inhibited Mouse Fibroblasts
Kedar, P. S., Stefanick, D. F., Horton, J. K., & Wilson, S. H. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0477 · Cited by 93
Chuang, H.-C., Kapuriya, N. P., Kulp, S. K., Chen, C., & Shapiro, C. L. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2106-5 · Cited by 92
Daniel, R. A., Rozanska, A. L., Thomas, H. D., Mulligan, E. A., Drew, Y., Castelbuono, D. J., Hostomský, Z., Plummer, E. R., Boddy, A. V., Tweddle, D. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1095 · Cited by 86
Mechanisms of Resistance to PARP Inhibitors—Three and Counting
Fojo, T., & Bates, S. E. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0514 · Cited by 79
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines
Davidson, D. L., Wang, Y., Aloyz, R. S., & Panasci, L. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9886-7 · Cited by 72
Shelton, J. W., Waxweiler, T. V., Landry, J., Gao, H., Xu, Y., Wang, L., El-Rayes, B., & Shu, H.-K. G. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.02.015 · Cited by 62 · cited 1×
“Indeed, recent publications show synergy between topoisomerase I inhibitors and veliparib in chemo-resistant colon cancer cell lines (in vitro and/or in vivo studies) (Zhang et al., 2011; Davidson et al., 2013; Shelton et al., 2013).”
BackgroundPredicting Enhanced Cell Killing through PARP Inhibition
Horton, J. K., & Wilson, S. H. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0512 · Cited by 52
Cited by
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,518
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
A decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743
“Although the precise mechanisms that explain PARP1 trapping are still unclear, two have been proposed: (i) PARPi either prevents the release of PARP1 from DNA by inhibiting autoPARylation [11] or (ii) PARPi binding to the catalytic site causes allosteric changes in the PARP1 structure enhancing DNA avidity [3, 10, 12].”
BackgroundLaying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Pommier, Y., O’Connor, M. J., & de Bono, J. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9246 · Cited by 739
Self-citationPARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 719
Metadata
- Authors
- Murai, J., Zhang, Y., Morris, J., Ji, J., Takeda, S., Doroshow, J. H., & Pommier, Y.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 349
- Issue
- 3
- Pages
- 408-416
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2139802796
- Cited by
- 293
- References
- 42
- FWCI
- 11.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.